Dianthus Therapeutics, Inc. (DNTH) Balance Sheet

NASDAQ: DNTHAssets, liabilities, debt and equity over 10 years.

DNTH balance sheet, 2025

December 31, 2025 · U.S. dollars

$530.9M assets = $37.5M liabilities + $493.4M equity

What it owns$530.9MCash & ST investments: $404.3M (76.1%)Cash & ST investments$404.3M · 76%Receivables: $102,000 (0.0%)Other current: $5.0M (0.9%)PP&E: $1.6M (0.3%)LT investments: $110.1M (20.7%)LT investments$110.1M · 21%Other non-current: $9.7M (1.8%)=How it is financed$530.9MCurrent liabilities: $30.7M (5.8%)Current liabilities $30.7MOther LT liabilities: $6.8M (1.3%)Shareholders’ equity: $493.4M (92.9%)Shareholders’ equity$493.4M · 93%

Both columns are drawn to the same scale: what DNTH owns equals what it owes plus shareholders’ equity. Hover a block for its value.

DNTH financial health

Debt / equity0.00
Low leverage · $0.00 of debt for each $1 of equity
Equity / assets92.9%
Equity-funded · of assets funded by shareholders
Cash / debt29,169.9%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

DNTH balance sheet trends, 2016–2025

Dianthus Therapeutics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$11.3M2016$530.9M2025+53.3%/yr
Total liabilities$2.3M2016$37.5M2025+36.4%/yr
Shareholders’ equity$9.0M2016$493.4M2025+56.0%/yr
Cash & short-term investments$4.5M2016$404.3M2025+64.7%/yr
Total debt$788,0002022$1.4M2025+20.7%/yr
Net cash (debt)$74.7M2022$402.9M2025+$328.2M
Working capital$8.5M2016$378.7M2025+$370.2M
Book value per share$10.582024$13.052025+23.4%/yr
Debt / equity0.0120220.002025−0.01
Shares outstanding33.3M202437.8M2025+13.4%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

DNTH assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

DNTH liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

DNTH debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

DNTH balance sheet

Dianthus Therapeutics, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$404.3M$275.2M$173.7M$75.5M$176.9M$148.8M$145.7M$142.6M$51.6M$4.5M
Cash & equivalents$51.1M$22.8M$132.3M$15.4M$131.7M$58.2M$65.1M$58.3M$51.6M$4.5M
Short-term investments$353.2M$252.4M$41.4M$60.1M$45.3M$90.7M$80.7M$84.2M——
Receivables$102,000$807,000$478,000$5.6M$1.5M$0$0$0$0$6.2M
Inventory$0$0$0$852,000$264,000$0$0$0$0$0
Other current assets$5.0M$4.9M$3.3M$53,000$2.0M$2.7M$4.1M$2.8M$936,000$41,000
Total current assets$409.4M$280.9M$177.5M$82.0M$180.7M$151.5M$149.8M$145.3M$52.5M$10.8M
Property, plant & equipment (net)$1.6M$1.7M$800,000$956,000$7.5M$8.3M$9.9M$3.1M$1.7M$508,000
Goodwill & intangible assets$0$0$0$0$0$0$0$0$0$0
Long-term investments$110.1M$81.7M$0$0$0$0$0$0$0$0
Other non-current assets$9.7M$9.6M$1.2M$121,000$1.8M$1.8M$1.8M$8.9M$222,000$0
Total assets$530.9M$374.0M$179.4M$83.1M$189.9M$161.6M$161.5M$157.3M$54.5M$11.3M
Liabilities
Accounts payable$9.7M$4.6M$2.6M$1.2M$3.0M$3.8M$2.8M$3.5M$167,000$1.7M
Short-term debt$367,000$320,000$417,000$350,000——————
Deferred revenue$1.2M$479,000$100,000$100,000——————
Total current liabilities$30.7M$18.5M$9.6M$8.2M$10.9M$11.4M$14.1M$10.4M$4.1M$2.3M
Long-term debt$0$0$0$0$0$0$0$0$0$0
Lease obligations$1.4M$1.5M$585,000$788,000$0—————
Other long-term liabilities$6.8M$3.1M$904,000$1.2M$6.4M$6.3M$6.2M$1.2M$0$0
Total liabilities$37.5M$21.5M$10.5M$9.5M$17.3M$17.7M$20.3M$11.7M$4.1M$2.3M
Shareholders' equity
Common stock & paid-in capital$43,000$31,000$15,000$61,000$59,000$49,000$39,000$33,000$6,000$3,000
Retained earnings (deficit)−$336.7M−$174.4M−$89.4M−$45.9M−$325.6M−$254.4M−$179.5M−$102.7M−$45.2M−$9.7M
Accumulated other comprehensive income$489,000$106,000$47,000−$161,000−$30,000−$23,000$8,000−$8,000−$382,000−$6,000
Total shareholders' equity$493.4M$352.5M$168.9M$73.7M$172.7M$143.9M$141.2M$145.6M$50.3M$9.0M
Key figures
Total debt$1.4M$1.5M$585,000$788,000——————
Net cash (debt)$402.9M$273.8M$173.1M$74.7M——————
Working capital$378.7M$262.5M$167.8M$73.8M$169.8M$140.1M$135.7M$134.9M$48.4M$8.5M
Tangible book value$493.4M$352.5M$168.9M$73.7M$172.7M$143.9M$141.2M$145.6M$50.3M$9.0M
Book value per share$13.05$10.58————————
Shares outstanding37.8M33.3M————————
Current ratio13.3215.2218.429.9716.6313.2610.6213.9512.684.71
Quick ratio13.1614.9618.099.8616.4213.0210.3213.6812.454.69
Debt / equity0.000.000.000.01——————
Equity / assets92.9%94.2%94.1%88.6%90.9%89.0%87.4%92.6%92.4%79.7%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 9, 2026); data from EODHD.

DNTH financial position

At the end of fiscal 2025 (December 31, 2025), Dianthus Therapeutics had total assets of $530.9 million (up 42.0% from a year earlier), total liabilities of $37.5 million and shareholders' equity of $493.4 million. It held $404.3 million in cash and short-term investments against $1.4 million of debt, a net cash position of $402.9 million. Its current ratio was 13.32. In the latest quarter (ended June 30, 2026) total assets were $1.2 billion and equity $1.2 billion.

Related: DNTH income statement, DNTH cash flow statement, DNTH key metrics. See the DNTH stock overview for the latest quote and news.

DNTH balance sheet FAQ

What are Dianthus Therapeutics's total assets?

Dianthus Therapeutics reported total assets of $530.9 million at the end of fiscal 2025 (December 31, 2025), compared with $374.0 million a year earlier.

How much debt does Dianthus Therapeutics have?

Dianthus Therapeutics had $1.4 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.00.

How much cash does Dianthus Therapeutics have?

Dianthus Therapeutics held $404.3 million in cash and short-term investments at the end of fiscal 2025; with $1.4 million of debt that is net cash of $402.9 million.

What is Dianthus Therapeutics's book value?

Dianthus Therapeutics's shareholders' equity (book value) was $493.4 million at the end of fiscal 2025, or $13.05 per share.

What is Dianthus Therapeutics's current ratio?

Dianthus Therapeutics had current assets of $409.4 million and current liabilities of $30.7 million, a current ratio of 13.32 (it can cover its short-term obligations).

Biotechnology: balance sheet